Aegis Capital Starts Progenics Pharmaceuticals (PGNX) at Buy

October 27, 2016 7:11 AM EDT
Get Alerts PGNX Hot Sheet
Price: $8.64 -0.35%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade PGNX Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Aegis Capital initiated coverage on Progenics Pharmaceuticals (NASDAQ: PGNX) with a Buy rating and a price target of $11.00.

For an analyst ratings summary and ratings history on Progenics Pharmaceuticals click here. For more ratings news on Progenics Pharmaceuticals click here.

Shares of Progenics Pharmaceuticals closed at $5.15 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Add Your Comment